Introduction Using oligonucleotide microarray, many IFNinducible genes have been found to be highly expressed in peripheral blood mononuclear cells (PBMCs) from most patients with systemic lupus erythematosus (SLE). Among these IFN-inducible genes, IFN-induced protein with tetratricopeptide repeats 4 (IFIT4) is a novel gene whose function is unknown.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multiple organ involvement, in which autoantibodies induce tissue damage. IFN-α/β [1, 2] and IFN-inducible genes (IFIGs) [3] [4] [5] are believed to play a major role in SLE.
IFN-α is a causative agent in the pathogenesis of SLE [6] [7] [8] . Elevated levels of IFN-α were detected in the sera of lupus patients [9] , and IFN-α levels in sera correlate with disease severity and the generation of autoantibodies [10] [11] [12] [13] . Patients treated with IFN-α occasionally develop antinuclear antibodies (ANAs), anti-double-stranded DNA antibodies (anti-dsDNAs) and autoimmune disorders [1, [14] [15] [16] [17] similar to those characteristic of SLE, but the mechanism by which IFN-α expression is associated with the generation of autoantibodies in vivo requires clarification [18] .
Notably, IFN-α/β was found to upregulate major histocompatibility complex expression and to induce differentiation of monocytes into dendritic cells (DCs) [19] [20] [21] [22] [23] [24] [25] [26] , antigen-presenting cells that induce and regulate immune responses. An increased number of circulating plasma cells and the presence of autoreactive T and B cells in the sera of patients with SLE suggest that the disease might be driven by alterations in DCs. Moreover, Blanco and coworkers [2] reported that IFN-α in the sera of SLE patients can induce normal monocytes to differentiate into DCs. Thus, IFN-α may enhance autoimmune responses in SLE by inducing DCs [27] . However, the mechanism by which IFN-α induces monocytes to differentiate into DCs has not been elucidated.
Recently, a gene expression study using an oligonucleotide microarray showed that many IFIGs are highly expressed in the peripheral blood mononuclear cells (PBMCs) of most SLE patients [3, 5, [28] [29] [30] [31] [32] , and IFIGs correlated with the production of autoantibodies and the clinical manifestations of SLE [3, 4, 18, 30, 31] . The IFIGs were thought to be responsible for the immunomodulatory properties of IFN, such as monocyte differentiation and anti-proliferation. For example, Ifi204 favours macrophage differentiation in myeloid progenitor cells [33] .
Among the IFIGs, IFN-induced protein with tetratricopeptide repeats 4 (IFIT4) is a novel gene whose function was unknown until recently, when it was shown to be a key mediator of antiproliferative activity by enhancing the p21 and p27 proteins [34, 35] . Induction of IFIT4 transcription by IFN-α depends upon the sequential activation of protein kinase Cδ, c-Jun amino-terminal kinase, and STAT1 (signal transducer and activator of transcription 1) [36] . Because IFIT4 can be induced by IFN-α [36] , which is involved in monocyte differentiation [2, 19, 20, 27, 37] , we were interested in testing whether IFIT4 was responsible for the effect of IFN-α on differentiation of monocytes into DCs [38] .
In the present study we found that increased expression of IFIT4 in the PBMCs of patients with SLE positively correlated with the presence of autoantibodies (ANA, anti-dsDNA and anti-Sm), leucocytopenia and hypocomplementaemia. Compared with DC-like cells (DCLCs) primed with pEGFP-C1 transfection, IFIT4-primed DCLCs exhibited higher expression of CD40, CD80, CD86 and HLA-DR; lower expression of CD14; enhanced IL-12 secretion; and increased ability to stimulate T-cell proliferation. This indicates that IFIT4 may play a role in promoting monocyte differentiation into DCs. Moreover, IFIT4-primed DCLCs induced a differentiation bias of CD4 + T cells into T-helper-1 (Th1) cells. These findings suggest that IFIT4 might play a role in the pathogenesis of SLE by promoting monocyte differentiation into DCs.
Materials and methods

Patients
A total of 108 patients with SLE and 46 normal healthy donors were recruited from the Department of Rheumatology, RenJi Hospital, which is affiliated with Shanghai Jiao Tong University School of Medicine (Table 1 ). All SLE patients fulfilled the diagnostic criteria of the American College of Rheumatology. All of study participants signed a patient material and informed consent form, approved by Renji Hospital Institutional Review Board.
Samples and clinical index
Human PBMCs were isolated by Ficolle-Hypaque density gradient separation. IFIT4 mRNA levels were detected by quantitative RT-PCR in total RNA, isolated from the PBMCs of 108 SLE patients and 46 healthy donors with Trizol reagent. IFIT4 protein expression levels were determined by Western blotting in protein samples from the PBMCs of 24 patients with SLE and 24 healthy control individuals.
Isolation of monocytes and T cells
Blood monocytes from three patients with SLE and three healthy control individuals were isolated using an immunomagnetic bead method (Miltenyi Biotec, Bergisch Gladbach, Germany) and were used to examine the expression of IFIT4 protein via Western blotting. CD4 + lymphocytes were purified from PBMCs via an indirect magnetic labeling system, namely the CD4 T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Purities were generally in excess of 95%. Freshly isolated T lymphocytes were used to measure mixed leucocyte responses (MLRs).
Quantitative real-time RT-PCR for mRNA
For quantitative analysis of gene expression, total RNA was isolated using a Trizol reagent kit (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized and fluorescence real-time RT-PCR was performed by using SuperScript™ III Platinum ® SYBR ® Green Two-Step qRT-PCR Kits (Invitrogen, Carlsbad, CA, USA) via the ABI PRISM 7900 system (Perkin-Elmer, Foster City, CA, USA). The following primers were used: IFIT4 for-ward: 5'-AACTACGCCTGGGTCTACTATCACTT-3'; IFIT4 reverse: 5'-GCCCTTTCATTTCTTCCACAC-3'; GAPDH forward: 5'-GAAGGTGAAGGTCGGAGTC-3'; GAPDH reverse: 5'-GAAGATGGTGATGGGATTTC-3'. All data were analyzed using ABI PRISM SDS 2.0 software (Applied Biosystems, Foster, CA, USA). Using the ΔCt method, GAPDH was coamplified to normalize the amount of RNA [39] .
Western blotting
Western blotting was performed as described previously [34, 39] . Protein from PBMCs and monocytes were harvested and transferred to polyvinylidene fluoride membranes. The membranes were incubated with monoclonal anti-human IFIT4 antibody (BD Clontech, Palo Alto, CA, USA) followed by horseradish peroxidase-linked secondary antibodies (Cell Signaling, Beverly, MA, USA). Equal protein loading for Western blots was confirmed by immunoblotting for β-actin.
Plasmid construction and transient transfection
The cDNA fragment encoding IFIT4 was amplified by PCR from a plasmid template (ORFEXPRESS™ Gateway ® ORF Shuttle Clones; GeneCopeia, Frederick, MD, USA), into which the full-length human IFIT4 cDNA was inserted. PCR products were digested by HindIII restriction endonuclease and cloned into the pEGFP-C1 vector, generating plasmid pEGFP-IFIT4. An endotoxin-free kit (EndoFree Plasmid isolation Kit, Qiagen, Chatsworth, CA, USA) was used to purify the vectors. pEGFP-C1 was used as a negative control (BD Clontech, Palo Alto, CA, USA). For transient transfections, the plasmids mentioned above were transfected into THP-1 cells using Lipofectamine 2000 (Invitrogen, USA) or Cell Line Nucleofector Kits V (Amaxa Biosystems, Cologne, Germany).
Confocal microscopy
To observe the subcellular location of IFIT4, THP-1 cells were transfected with pEGFP-IFIT4 or pEGFP-C1 empty vector. Forty eight hours later, cells were stimulated with 3000 μ/ml IFN-α for 3 days. The cells were examined under a confocal microscope (Leica TCS SP2, Leica Microsystems, Heidelberg, Germany), using DAPI for nuclear staining.
Cell culture and generation of IFIT4-primed dendritic cell-like cells from THP-1 cells
The human monocytic cell line THP-1 (ATCC, Manassas, VA, USA) [40] was cultured in RPMI 1640 (Hyclone, Logan, UT, USA) supplemented with 10% foetal bovine serum and 2 mmol/l L-glutamine at 37°C in 5% carbon dioxide. The following human recombinant cytokines were used as stimulators: recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/ml), IL-4 (20 ng/ml; R&D Systems, Minneapolis, MN, USA), and lipopolysaccharide (LPS; 100 ng/ml, Escherichia coli 0111:B:4; Sigma, St. Louis, MO, USA).
To generate DC-like cells (DCLCs), THP-1 cells were treated with GM-CSF and IL-4 (GM-CSF/IL-4) [40] [41] [42] [43] [44] at the indicated concentrations for up to 6 to 12 days. To generate IFIT4-primed DCLCs, THP-1 cells were transfected with pEGFP-IFIT4; 36 hours later the cells were stimulated with GM-CSF/IL-4 for up to 5 to 7 days. The DCLCs derived from THP-1 transfected with pEGFP-C1 were designated controls. Mature and active DCLCs were generated from THP-1 cells that were treated with GM-CSF/IL-4 for 6 to 12 days and further cultured with LPS for an additional 2 days. Cultures were fed every 2 or 3 days by removing half of the medium and adding fresh medium with full doses of cytokines.
Morphological examination
To assess the effect of IFIT4 on monocyte differentiation, the morphology of DCLCs primed by transfection with pEGFP-C1 or pEGFP-IFIT4 was examined every day using an Olympus IX-70 inverted microscope 
Monoclonal antibodies and flow cytometry
Mixed leucocyte responses
Mature and active DCLCs, generated as described above, were harvested and γ-irradiated (3,000 rads) followed by incubation with 5 × 10 4 allogeneic CD4 + T cells/well, at ratios of DCLCs to T cells of 1:10, 1:20 and 1:40. Three days later, [ 3 H]thymidine was added (0.5 μCi/well) and the cells were incubated for another 18 hours. The cells were harvested and the incorporated radioactivity measured using a β counter (model LS3801; Beckman Coulter, Brea, CA, USA).
Responses were reported as the mean of triplicate samples (mean [counts/minute cpm] ± standard deviation).
Enzyme-linked immunosorbent assay
Mature and active DCLCs were generated as described above. Total IL-12 (p40 and p70) secreted by DCLCs primed with pEGFP-IFIT4 or pEGFP-C1 transfection was measured with the BIOSOURCE IL-12+p40 ELISA kit (Biosource Europe S.A., Nivelles, Belgium) [45] .
To examine the effect of IFIT4-primed DCLCs on T-cell polarization, T cells (2 × 10 5 /well) were plated and cultured with γ-irradiated IFIT4-primed DCLCs at a ratio of DCLCs to T cells of 1:10 for 6 days. 10 ng/ml of phorbol 12-myristate 13-acetate (PMA) was added and the cells cultured for 1 more day. The supernatants were harvested to measure the concentrations of IL-4 and IFN-γ by using the Human IL-4/IFN-γ ELISA Kit (Biosource Europe S.A.).
Statistical analysis
Two group comparisons of gene expression were assessed using unpaired t-test, or the nonparametric Mann-Whitney test when the data did not have a normal distribution [3, 18, 46, 47] .
Results are presented as the mean ± standard deviation unless specified otherwise. Correlations of IFIT4 mRNA expression levels with titre of auto-antibodies and SLE Disease Activity Index (SLEDAI) scores were determined using Spearman's rank correlation coefficient [47] .
Results
Increased expression of IFIT4 mRNA and protein in PBMCs and monocytes from SLE patients A total of 108 SLE patients and 46 healthy donor individuals were matched for both age and sex ( Table 1) . The results of real-time quantitative RT-PCR revealed that the means of IFIT4 relative mRNA levels were 37.84 ± 3.52 in PBMCs from SLE patients and 10.58 ± 2.64 in those from healthy control individuals, and the difference was statistically significant (P < 0.001; Figure 1a ). IFIT4 protein levels, examined using Western blotting, were significantly increased in PBMCs from 24 SLE patients than in those from the 24 healthy control individuals (P < 0.05; Figure 1b ,c). In addition, IFIT4 protein levels in the monocytes of SLE patients were significantly increased compared with those in control individuals (P < 0.05; Figure  1d ).
Increased expression of IFIT4 is associated with autoantibodies in SLE
Spearman's correlation analysis was carried out to determine the relationship between IFIT4 expression and the clinical characteristics of SLE. We found that IFIT4 mRNA relative expression correlated with ANA titre in 108 SLE patients (r = 0.4783, P < 0.001; Figure 2a) , and with anti-dsDNA autoantibody titre in 36 SLE patients (r = 0.3932, P < 0.05; Figure  2b ), and with anti-Sm antibody titre in seven SLE patients (r = 0.9088, P < 0.01; Figure 2c ). Moreover, SLE patients who were positive for anti-dsDNA autoantibodies had higher IFIT4 expression than did those who were negative (P = 0.0277; Figure 2d ). The difference in IFIT4 expression between patients who were positive or negative for anti-Ro (anti-SSA; Figure 2e ) or anti-aCL/β2-GP1 (Figure 2f ) was not statistically significant (P > 0.05). Our findings suggest that higher IFIT4 expression is associated with a greater likelihood of having autoantibodies against ribonucleoproteins.
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Correlation between the expression of IFIT4 and clinical manifestation in SLE In the SLE population as a whole, we found that SLE patients with hypocomplementaemia or leucopenia or/and thrombocytopenia usually had higher IFIT4 mRNA relative expression than did SLE patients without these disorders (P = 0.0121, Figure 2g ; P = 0.0301, Figure 2h ). However, IFIT4 expression in PBMCs from SLE patients with or without nephritis was not statistically different (P > 0.05; Figure 2i ). We found no correlation between IFIT4 gene expression and scores of the SLEDAI-2K in 108 SLE patients (r = 0.0574, P > 0.05; Figure  2j ).
IFIT4 protein is expressed predominantly in immune tissues and cells, and exclusively localized in the cytoplasm IFIT4 was examined using real-time quantitative RT-PCR and was found to be predominantly expressed in seven out of 14 normal human tissues, namely spleen, lung, leucocytes, lymph nodes, placenta, bone marrow and foetal liver (in order of the highest to the lowest), most of which belong to the immune system (P < 0.05; Figure 3a ). Rather than being restricted to one immune cell, IFIT4 was expressed in many immune cells, including CD19 + , CD8 + , CD14 + and CD4 + cells (P < 0.05; Figure 3b ).
To determine the the subcellular localization of IFIT4 protein, THP-1 cells were transfected with pEGFP-C1 or pEGFP-IFIT4 plasmid and examined by confocal microscopy ( Figure 3c ). In contrast to the pEGFP-C1 group, in which EGFP (enhanced green fluorescent protein) was dispersed throughout the cell (Figure 3c 
Effect of IFIT4 on the morphological changes in the differentiation of monocytes into dendritic cells
Because it is usually difficult to transfect primary monocytes, we chose an appropriate monocytic cell line, namely THP-1, which has a suspended, rounded appearance and is widely used as a model for monocyte-macrophage differentiation [42] [43] [44] 48, 49] . We confirmed that THP-1 cells have the potential to differentiate into mature DCLCs with various characteristics of DC morphology (data not shown) after 12 days of treatment with GM-CSF/IL-4 followed by stimulation with LPS for another 2 days. An effect of IFIT4 on monocyte differentiation into DCs in terms of morphological changes was observed. Upon treatment with GM-CSF/IL-4 for 86 hours, no DC IFIT4 protein expression levels were detected using Western blotting. β-Actin was used as a protein loading control. A set of random data from eight SLE patients and eight HD controls is presented (P = 0.002, Mann-Whitney test). (d) Monocytes from three SLE patients and three HDs were isolated using magnetic beads. The IFIT4 protein expression level in these monocytes was determined by Western blotting. IFIT4, interferon-induced protein with tetratricopeptide repeats 4.
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Figure 2
Correlation analysis between IFIT4 expression and clinical assessments in SLE patients Correlation analysis between IFIT4 expression and clinical assessments in SLE patients. Total RNA from the peripheral blood mononuclear cells (PBMCs) of 108 systemic lupus erythematosus (SLE) patients and 46 healthy donors (HDs) was isolated, and the relative expression levels of IFIT4 mRNA were determined using real-time quantitative RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was coamplified as an internal control to normalize the amount of RNA. In the total SLE population, the relative expression of IFIT4 was plotted against the following: (a) the titre of antinuclear antibody (ANA) in a group of 108 SLE patients; (b) the titre of anti-double-stranded DNA antibody (anti-dsDNA) in 36 SLE patients; and (c) the titre of anti-Smith antibody (anti-Sm) in 7 SLE patients. Spearman's correlation test was used to analyze these data. In the SLE population as a whole, the relative expression of IFIT4 was determined using real-time quantitative RT-PCR in patients who were positive or negative for the follow- 
Effects of IFIT4 on increasing the expression of costimulatory molecules in DCLCs
We first assessed the expression background of related surface markers of THP-1 cells by FACS. We found that CD14 was expressed at high levels, whereas CD80, CD86, CD1a and CD1b were expressed at lower levels on the surface of intact THP-1 cells (Figure 5a ), confirming that THP-1 cells were more consistent with a monocytic than a dendritic phenotype. To determine the effect of IFIT4 on DC differentiation in terms of cell phenotypic changes, THP-1 cells primed with pEGFP-C1 or pEGFP-IFIT4 transfection were treated with GM-CSF/IL-4 for 90 hours; the cell surface markers were analyzed by flow cytometry. We found that DCLCs primed with pEGFP-IFIT4 transfection expressed higher levels of CD40, CD80, CD86 and HLA-DR, but lower levels of CD14 than did those DCLCs primed with pEGFP-C1 transfection upon the same GM-CSF/IL-4 stimulation (P < 0.05; Figure 5b ). There was no change in CD1a expression between the two groups ( Figure 5b ).
Effect of IFIT4 in terms of enhancing the ability of DCLCs to present antigens to T cells
To examine further the effect of IFIT4 on modulating the ability of DCLCs to activate T-cell proliferation, an allogeneic MLR assay was conducted. Mature DCLCs primed with pEGFP-IFIT4 or pEGFP-C1 were generated with 6 days of GM-CSF/ IL-4 stimulation and further treatment with 2 days of LPS, and then these DCLCs were cultured with allogeneic CD4 + cells with different ratios of DCLC to T cells. As shown in Figure 6a , the extent of T-cell proliferation induced by DCLCs primed with pEGFP-IFIT4 transfection was significantly higher than those induced by DCLCs primed with pEGFP-C1, indicating that IFIT4-primed DCLCs had a greater ability to induce T-cell proliferation than controls (Figure 6a ; P < 0.05).
Effect of IFIT4 on IL-12 secretion by activated DCLCs
To determine the effect of IFIT4 on IL-12 secretion by activated DCLCs, THP-1 cells transfected with pEGFP-IFIT4 or pEGFP-C1 were stimulated with GM-CSF/IL-4 for 6 days and further treated with LPS for 2 days (1 × 10 5 cells/ml) to generate mature, activated DCLCs. We found that the mature and activated IFIT4-primed DCLCs produced more IL-12 than did DCLCs primed with pEGFP-C1 transfection (Figure 6b ; P < 0.05).
TH1 polarization by IFIT4-primed DCLCs
To address whether IFIT4 modulates the capacity of DCLCs to direct T-helper cell differentiation, mature and activated DCLCs were generated as described above. Then these mature DCLCs were γ-irradiated followed by incubation with T cells for 6 days. The ELISA findings revealed that T cells that were stimulated with IFIT4-primed mature DCLCs secreted more IFN-γ (about 2.4-fold) than did those stimulated with DCLCs primed with pEGFP-C1 transfection (P < 0.05; Figure  6c ). We did not find that any of the DCLCs affected IL-4 secretion to a significant degree (Figure 6c ; P > 0.05).
Discussion
SLE is an autoimmune disease that is characterized by a break in tolerance to nuclear components and by multi-tissue damage. The pathogenesis of SLE has not been fully elucidated.
Increased expression of a spectrum of IFIGs in SLE [3, [30] [31] [32] , the inherent responsiveness of these genes to Type I Interferon (IFN-I) [29, 30] , and the correlation between IFN-I or IFIGs and production of autoantibodies or disease severity [18, 50] indicate a coordinated activation of the IFN-I pathway globally and a role for IFIGs in the pathogenesis of SLE [5, 18] . In this study we found evidence that IFIT4, which was highly expressed in patients with SLE, is associated with the presence of autoantibodies and hypocomplementaemia as well as haematocytopenia. Most notably, IFIT4 might play a role in monocyte differentiation into DCs, and hence contribute to the mechanism by which autoantibodies become elevated and some of the clinical manifestations present in SLE.
We confirmed that IFIT4 mRNA and protein were significantly increased in PBMCs from SLE patients and positively correlated with the presence of ANA, anti-dsDNA and anti-Sm/RNP antinucleoprotein autoantibodies, which indicates that a role of IFIT4 in the pathogenesis of SLE might be directly or indirectly associated with the production of autoantibodies. SLE patients with higher expression of IFIT4 exhibited a greater prevalence of hypocomplementaemia, leucopenia and thrombocytopenia. The function of IFIT4 in antiproliferation [34] might be partially responsible for the haematocytopenia observed in patients with SLE, which requires further study in the future. There was no apparent relationship between IFIT4 expression and the presence of renal disease or SLEDAI. The clinical characteristics of IFIT4 are similar to those of another IFIG, namely Mx1, whose expression is also positively associated with autoantibodies against SM/RNP and dsDNA, but not with SLEDAI or the presence of renal disease [4] . IFN-α score [18] was derived from many IFIGs (PRKR, IFIT1 and IFI44) as measured by quantitative real-time PCR and represented the global activation of IFN-I pathway [3, 18, 29, 30, 51] ,. We presumed that, unlike the IFN-α score, IFIT4 or Mx1, as individual IFIG, was unable to be suggested to exclusively determine the global and comprehensive disease manifestation, severity and activity or even organ damage.
IFIT4 was found to be predominantly expressed in immune tissues and cells, indicating a potential role for IFIT4 in immune response. Both its extranuclear localization and its tetratricopeptide repeat motifs provide some clues that emphasize the role played by IFIT4 in the interaction between proteins via its tetratricopeptide repeat domain. That no translocation into nucleus took place after stimulation with IFN-α indicates that IFIT4 required other protein interaction partners to transport information into the nucleus. IFIT4 was markedly induced by IFN-α in normal PBMCs, indicating a role for IFIT4 as a downstream effector of IFN-α [28, 29] .
Both IFN-α [16, 17, 46] and IFIT4 were related to the presence of autoantibodies. IFN-α might indirectly contribute to the generation of autoantibodies by inducing monocytes to differentiate into DCs [2, 41, 52, 53] . Our results showed that IFIT4 might be responsible for monocyte differentiation as a downstream effector of IFN-α. We found that the IFIT4-primed DCLCs, in which IFIT4 was over-expressed, adopted DC morphology sooner and exhibited a greater resemblance to DCs than did DCLCs that were primed with control pEGFP-C1 transfection, in terms of becoming half adherent and developing dendrites (Figure 4 ). This indicates that IFIT4 promoted the morphological changes that occurred during differentiation of monocytes into DCs. Furthermore, compared with control DLCLs, IFIT4-primed DCLCs exhibited a pattern of surface markers that was more consistent with DCs, including greater expression of the co-stimulatory molecules CD40, CD80, CD86, HLA-DR and CD83, along with more obvious downregulation of the monocytic marker CD14 ( Figure 5 ). Moreover, activated IFIT4-primed DCLCs induced stronger MLR and produced more IL-12 than did control cells ( Figure 6 ).
Collectively, these effects of IFIT4 on morphology, phenotype, antigen-presenting ability and IL-12 production of monocytes suggest that IFIT4 might play a role in promoting monocyte differentiation into DCs. This is because IFIT4-primed cells acquired more cytoplasmic protrusions or dendrites; more expression of the co-stimulatory molecules CD40, CD80, CD86, HLA-DR and CD83; lower expression of CD14; stronger antigen-presenting ability; and more IL-12 production. All of these are among the key characteristics of immature or mature DCs. Moreover, IFIT4-primed DCLCs stimulated greater IFN-γ secretion by T cells, which suggests that IFIT4 might direct DCs to modulate Th1 cell differentiation and favour the ability of DCs to skew the immune response toward Th1 development.
It was shown that monocytes from patients with SLE had severely altered phenotype and lineage flexibility, and might act as DCs [54, 55] . For instance, they expressed significantly lower levels of CD14 [54] and were able to induce strong MLR [2] , although HLA-DR levels were similar to [55] or lower than [54, 56] those of controls. The effect of IFIT4 on monocyte differentiation into DCs was suggested to be partially responsible for this unbalanced function of monocytes and DCs in SLE [2] . The function of IFIT4 on differentiation and anti-proliferation [34] indicated that IFIT4 might act as a regulator to balance proliferation and differentiation.
How might IFN-α and IFIT4 contribute to the pathogenesis of SLE? Our hypothesis is that IFN-α and IFIT4 may act as 'adju- Mature and activated DCLCs primed with pEGFP-C1 or pEGFP-ITFIT4 transfection were generated as described above. Then these mature and activated DCLCs were γ-irradiated and cultured with T cells at a ratio of DCLCs to T cells of 1:10 for 6 days. Phorbol-12-myristate-13-acetate (PMA) (10 ng/ml) was added for another day. Finally, the culture medium was measured to assess IFN-γ and IL-4 produced by T cells by ELISA (T cells: 2 × 10 5 cells/ml; DCLC to T cell ratio = 1:10 vant'-like factors [21] to convert an immune system that ignores self-antigens into an immune system that actively recognizes these antigens by promoting DC differentiation, maturation and activation [21, 57] . The activated DCs may present ribonucleoprotein antigens in an immunogenic rather than tolerogenic manner, leading to the activation of autoreactive T cells that 'help' to drive autoantibody production in B cells [58] .
Conclusion
Our results indicate that IFIT4 might contribute to the pathogenesis of SLE by inducing monocytes to differentiate into DCs. This provides insight into the pathogenesis of SLE and might lead to novel treatments [25, 59] .
